Premium
BROMOCRIPTINE AND DOPAMINE RECEPTOR STIMULATION
Author(s) -
DEBONO A. GALEA,
MARSDEN CD.,
ASSELMAN P.,
PARKES J.D.
Publication year - 1976
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1976.tb00346.x
Subject(s) - bromocriptine , stimulation , dopamine receptor , dopamine , dopamine receptor d2 , pharmacology , medicine , neuroscience , endocrinology , psychology , prolactin , hormone
1 The response to different doses of bromocriptine (12.5, 25, 50 and 100 mg) has been established in six patients with Parkinson's disease. 2 Bromocriptine, like levodopa, causes improved mobility in patients with Parkinsonism, emesis, hallucinations, a fall in supine and erect blood pressure, increase of plasma growth hormone and suppression of prolactin concentration. 3 Bromocriptine (50 or 100 mg) has as great an anti‐Parkinsonian effect as average therapeutic doses of levodopa, and a longer duration of action, 6–10 hours. 4 In the dose range studied, bromocriptine appears to be a complete dopamine agonist, although 100 mg was less effective than 50 mg in two patients. 5 The different actions of bromocriptine and other dopamine agonist drugs may result from stimulation of different types of dopamine receptor.